Effect of an Antidiencephalon Immune Serum on Pain and Sleep in Primary Fibromyalgia
ABSTRACT The results of a double-blind, randomized, therapeutical trial with SER282, an antidiencephalon immune serum (Serolab, Lausanne, Switzerland), in 36 women, aged 24-56 years, with primary fibromyalgia are presented. Treatment was ambulatory and consisted of either SER282 (20 mg/ml) or amitryptiline (AMI, 50 mg) or placebo (PL) over an 8-week treatment course. Clinical and sleep EEG polygraphic data were obtained at baseline and after 4 and/or 8 weeks of therapy. Compared to an important PL response and moderate analgesia with AMI, pain and associated symptoms improved moderately with SER282. In contrast, polysomnographic recordings showed that SER282 tended to promote stage 4 sleep, while AMI and PL had few--if any--effect on sleep. These results are discussed together with the clinical characteristics of the patients and the relations between pain, associated symptoms, and sleep parameters in our patient population.
Full-textDOI: · Available from: Viviane de maertelaer, May 24, 2014
Click to see the full-text of:
Article: Effect of an Antidiencephalon Immune Serum on Pain and Sleep in Primary Fibromyalgia
- SourceAvailable from: PubMed Central
[Show abstract] [Hide abstract]
- "A third meta-analysis of antidepressants in the treatment of fibromyalgia  evaluated 13 trials of antidepressants, most of which studied the cyclic drugs amitriptyline [17-20,26,29-32], clomipramine , and maprotiline . The meta-analysis also included trials of the selective serotonin reuptake inhibitors (SSRIs) fluoxetine [20,33] and citalopram , as well as a reversible inhibitor of the monoamine oxidase-A enzyme, moclobemide , and the dietary supplement S-adenosylmethionine [35,36]. "
ABSTRACT: Fibromyalgia is a chronic, musculoskeletal pain condition that predominately affects women. Although fibromyalgia is common and associated with substantial morbidity and disability, there are no US Food and Drug Administration-approved treatments. However, progress has been made in identifying pharmacological and non-pharmacological treatments for fibromyalgia. Recent pharmacological treatment studies have focused on selective serotonin and norepinephrine reuptake inhibitors, which enhance serotonin and norepinephrine neurotransmission in the descending pain pathways and lack many of the adverse side effects associated with tricyclic medications. Promising results have also been reported for medications that bind to the alpha2delta subunit of voltage-gated calcium channels, resulting in decreased calcium influx at nerve terminals and subsequent reduction in the release of several neurotransmitters thought to play a role in pain processing. There is also evidence to support exercise, cognitive behavioral therapy, education, and social support in the management of fibromyalgia. It is likely that many patients would benefit from combinations of pharmacological and non-pharmacological treatments, but more study is needed.Arthritis research & therapy 02/2006; 8(4):212. DOI:10.1186/ar1971 · 3.75 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Background A retrospective study was carried out in 42 outpatients with age-related macular degeneration to assess the effectiveness and tolerance of tissue antisera "OEil" and tissue antisera "Neurovasculaire".
- [Show abstract] [Hide abstract]
ABSTRACT: Despite significant efforts devoted to understanding the etiopathogenesis of fibromyalgia, its treatment still presents a challenge to practicing clinicians, who must recognize the disorder and quantify the different symptoms in order to treat it. This article discusses recent research to identify sensitive and reliable measures for determining response to treatment among patients with FM, and the elements of therapeutic programs (pharmacologic and nonpharmacologic) for patients with FM along with the empirical or theoretical basis for their use. Future directions, including the need for systematic, controlled outcome studies of therapies and evaluation of variables which may mediate the effects of treatment, as well as demonstration that the effects produced in outcome studies generalize to settings beyond those in which the studies are initially conducted, are also discussed.The American Journal of the Medical Sciences 07/1998; 315(6):397-404. DOI:10.1097/00000441-199806000-00008 · 1.39 Impact Factor